12706 Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices 

Partner and Sexual Violence Survey 

(NISVS) (OMB Control No. 0920–0822, 

Exp. 03/31/2023). NISVS is a 

surveillance system used to monitor the 

magnitude of sexual violence (SV), 

stalking, and intimate partner violence 

(IPV) victimization among adults in the 

U.S. This Revision is being requested to 

continue collection of this data 

annually. Data are used by the federal 

government, states, partner 

organizations, and stakeholders to 

inform prevention programs and 

policies related to SV, stalking, and IPV. 

Additionally, NISVS data will be used 

in training programs, peer reviewed 

journals, technical reports, factsheets 

and other media. Datasets are made 

public for external researchers to use as 

well. NISVS data has also been used in 

the context of health equity by looking 

at race and ethnicity and sexual 

orientation. In 2010, NISVS collected 

data for the National Institute of Justice 

(NIJ) to examine IPV, SV, and stalking 

among American Indian and Alaska 

Native people. NISVS collected data in 

2010, and again in 2016–17 for the 

Department of Defense (DoD) to 

understand the prevalence of violence 

among active-duty women, active-duty 

men, and the wives of active-duty men. 

Continuing to document and monitor 

the prevalence of IPV, SV, and stalking 

is a critical step to improving the health 

of individuals, making communities 

safer, and reducing the social and 

healthcare costs currently burdening 

state and federal governments and 

programs. NISVS data can be used to 

inform public policies and prevention 

strategies and to help guide and 

evaluate progress towards reducing the 

substantial health and social burden 

associated with IPV, SV, and stalking. 

The modification in this Revision 

request is to fully implement the 

redesigned methodology and 

questionnaire for full national-level data 

collection. The redesigned NISVS will 

use an address-based sampling frame 

with push-to-web collection and 

optional call-in telephone option, 

increasing the response rate, decreasing 

costs, and reducing respondent burden. 

NISVS data will be collected using 

address-based randomized sampling 

with push-to-web design, whereby 

respondents will complete the survey 

on the internet. A call-in telephone 

option will be available to those who 

prefer to take the survey by phone. 

The subpopulation to be studied is 

non-institutionalized, English- and 

Spanish-speaking women and men aged 

18 years or older in the United States. 

Data are analyzed using appropriate 

statistical software to account for the 

complexity of the survey design to 

compute weighted counts, percentages, 

and confidence intervals using national 

and state-level data. 

CDC requests OMB approval for an 

estimated total of 7,938 annualized 

burden hours. There are no costs to 

respondents other than their time to 

participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden 

per response 

(in hours) 

Total 

burden 

(in hours) 

Individuals and Households .............. Letter ................................................ 15,000 1 6/60 1,500 

Screener ........................................... 15,000 1 3/60 750 

Web Questionnaire .......................... 14,250 1 25/60 5,938 

Phone Questionnaire ....................... 750 1 40/60 500 

Total ........................................... ........................................................... ........................ ........................ ........................ 7,938 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–04669 Filed 3–4–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–22–1335] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

submitted the information collection 

request titled ‘‘CDC’s COVID–19 

Program for Cruise Ships Operating in 

U.S. Waters’’ to the Office of 

Management and Budget (OMB) for 

review and approval. CDC previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on April 30, 

2021, to obtain comments from the 

public and affected agencies. CDC 

received 20 comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices 12707 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

CDC’s COVID–19 Program for Cruise 

Ships Operating in U.S. Waters (OMB 

Control No. 0920–1335, Exp. 4/30/ 

2022)—Extension—National Center for 

Emerging Zoonotic and Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

As the COVID–19 pandemic has 

unfolded, this information collection 

has evolved. CDC’s COVID–19 

regulatory requirements in the 

Framework for a Conditional Sailing 

Order (CSO) expired on January 15, 

2022, at 12:01 a.m. EST. CDC is 

transitioning to a new COVID–19 riskmitigation program for cruise ships 

operating in U.S. waters. Cruise ship 

operators will have the option to 

participate in this program at their 

discretion. This program will include 

recommendations and guidance for 

cruise ships to continue to operate in a 

way that provides a safer and healthier 

environment for crew, passengers, and 

communities. 

Through the implementation of the 

CSO, CDC has identified best practices 

for controlling the spread of COVID–19 

on cruise ships and has coordinated 

with cruise ship operators and other 

stakeholders to implement these 

measures. CDC remains committed to 

working with the cruise industry, state, 

territorial, and local health authorities, 

and seaport partners to continue to 

implement these measures. 

Cruise ship operators choosing to 

participate in the CDC’s COVID–19 

Program for Cruise Ships Operating in 

U.S. Waters on a voluntary basis agree 

to follow all recommendations and 

guidance issued by CDC as part of this 

program. These recommendations are 

aimed at further reducing the 

introduction and spread of SARS–CoV– 

2 onboard. CDC will work closely with 

cruise ships opting into the program and 

continue to monitor compliance with 

COVID–19 preventive measures and 

cases onboard these cruise ships 

through daily enhanced data collection 

and inspections. 

Cruise lines that decide not to 

participate in CDC’s COVID–19 Program 

for Cruise Ships Operating in U.S. 

Waters will receive a designation 

showing that CDC has neither reviewed 

nor confirmed the cruise ship operator’s 

COVID–19 health and safety protocols. 

Additionally, these ships will be subject 

to other CDC orders and regulations to 

the same extent as other ships and 

conveyances subject to the jurisdiction 

of the United States. 

The guidance and recommendations 

included in CDC’s COVID–19 Program 

for Cruise Ships Operating in U.S. 

Waters are aligned with previous health 

and safety protocols under the CSO. As 

such, cruise ship operators who have 

resumed operations under the CSO will 

already be familiar with the components 

of the program, and operators who 

choose to participate in the program 

will be able to continue sailing with 

passengers without interruption. 

This information collection request 

outlines the reporting and document 

retention requirements that are part of 

CDC’s COVID–19 Program for Cruise 

Ships Operating in U.S. Waters. Note, 

many of the data collection elements 

included in CDC’s COVID–19 Program 

for Cruise Ships are currently approved 

as part of OMB Package 0920–1335 

Phased Approach to the Resumption of 

Cruise Ship Passenger Operations, 

submitted on April 30, 2021. 

CDC will provide cruise ship 

operators with information about the 

program and how to contact CDC to opt 

in or opt out of the program. 

Opting Into the COVID–19 Program for 

Cruise Ships 

Cruise lines operating cruise ships in 

U.S. waters choosing to participate in 

this program (‘‘opting in’’) are requested 

to notify the CDC in writing of their 

decision to opt in by February 18, 2022. 

Cruise lines choosing to participate in 

this program will be required to follow 

all recommendations and guidance as a 

condition of their participation—i.e., 

they will not be able to pick and choose 

which recommendations they follow. 

Those opting in will continue to receive 

a color status for cruise ships operating 

in U.S. waters on CDC’s Cruise Ship 

Color Status web page. 

Cruise lines with ships not currently 

in U.S. waters—but that are expecting to 

return to U.S. waters after February 18, 

2022—are requested to contact CDC via 

email at least 28 days prior to their 

ships’ arrival. Instructions on how to 

participate in the program will be 

provided. 

Cruise lines that initially decide to 

participate in the program but then later 

decide not to participate should contact 

CDC via email for instructions. 

Opting Out of the COVID–19 Program 

Cruise lines operating in U.S. waters 

choosing not to participate in the 

program (‘‘opting out’’) are requested to 

notify CDC in writing by February 18, 

2022. 

Cruise lines that do not notify CDC by 

5:00 p.m. ET on February 18, 2022, will 

be considered to have opted out of this 

program. Cruise lines that decide to opt 

out will have any cruise ships operating 

in U.S. waters listed as ‘‘Gray’’ ships on 

CDC’s Cruise Ship Color Status web 

page. This designation means that CDC 

has neither reviewed nor confirmed the 

cruise ship operator’s health and safety 

protocols. Additionally, these ships will 

be subject to other CDC orders and 

regulations to the same extent as other 

ships and conveyances subject to the 

jurisdiction of the United States. 

Cruise lines that initially decide to 

opt out but later decide to opt into the 

program should contact CDC via email 

at least 28 days prior to the day they 

intend to join the program. Instructions 

on how to participate in the program 

will be provided. 

Cruise Ship Vaccination Status 

Classification 

Cruise lines that choose to participate 

in CDC’s COVID–19 Program for Cruise 

Ships Operating in U.S. Waters must 

advise CDC of the vaccination status 

classification for each participating 

ship. This information will be included 

on CDC’s Cruise Ship Color Status 

webpage. 

As part of CDC’s COVID–19 Program 

for Cruise Ships Operating in U.S. 

Waters, cruise ship vaccination status 

classifications are defined as: 

• Not Highly Vaccinated: Ships with 

less than 95% of passengers and 95% of 

crew who are fully vaccinated. 

Æ Cruise ship operators that select 

this vaccination status classification 

will be required to enforce mask use and 

physical distancing onboard according 

to CDC guidance. 

• Highly Vaccinated: Ships with at 

least 95% of passengers and 95% of 

crew who are fully vaccinated, but less 

than 95% of passengers and 95% of 

crew are up to date with their COVID– 

19 vaccines. 

Æ Cruise ship operators that select 

this vaccination status classification 

will be required to enforce mask use— 

but not physical distancing—onboard 

according to CDC guidance. These 

cruise ship operators may implement 

physical distancing policies at their 

discretion. 

• Vaccination Standard of Excellence: 

Ships with at least 95% of passengers 

(including children) and 95% of crew 

who are up to date with their COVID– 

19 vaccines. 

Æ Cruise ship operators that select 

this vaccination status classification 

will not be required to enforce mask use 

or physical distancing onboard. These 

cruise ship operators may implement 


khammond on DSKJM1Z7X2PROD with NOTICES
12708 Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices 

mask use and physical distancing 

policies at their discretion. 

Ships adhering to the ‘‘Highly 

Vaccinated’’ or ‘‘Vaccination Standard 

of Excellence’’ classifications must 

maintain these thresholds for each 

voyage. 

COVID–19 Response Plans 

Cruise ship operators choosing to 

participate in CDC’s COVID–19 Program 

for Cruise Ships Operating in U.S. 

Waters must have a COVID–19 response 

plan that includes the following 

components: 

• Terminology and use of definitions 

that align with how CDC uses and 

defines the following terms: ‘‘Confirmed 

COVID–19,’’ ‘‘COVID–19-like illness,’’ 

‘‘close contact,’’ ‘‘fully vaccinated for 

COVID–19,’’ and ‘‘isolation’’ and 

‘‘quarantine’’ (including timeframes for 

isolation and quarantine). 

• Protocols for on board surveillance 

of passengers and crew with COVID–19 

and COVID–19-like-illness. 

• Protocols for training all crew on 

COVID–19 prevention, mitigation, and 

response activities. 

• Protocols for on board isolation and 

quarantine, including how to increase 

capacity in case of an outbreak. 

• Protocols for COVID–19 testing that 

aligns with CDC technical instructions. 

• Protocols for onboard medical 

staffing—including number and type of 

staff—and equipment in sufficient 

quantity to provide a hospital level of 

care (e.g., ventilators, face masks, 

personal protective equipment) for the 

infected without the immediate need to 

rely on shoreside hospitalization. 

• Procedures for disembarkation of 

passengers who test positive for COVID– 

19. 

• Statement that the cruise ship 

operator has observed and will continue 

to observe all elements of its COVID–19 

response plan including following the 

most current CDC recommendations and 

guidance for any public health actions 

related to COVID–19. 

Surveillance and Reporting 

For cruise ships that have chosen to 

participate in the program, CDC requires 

daily submission of the ‘‘Enhanced Data 

Collection (EDC) During COVID–19 

Pandemic Form’’, in lieu of submitting 

the Maritime Conveyance Cumulative 

Influenza/Influenza-Like Illness (ILI) 

Form for COVID–19-like illness and the 

Maritime Conveyance Illness or the 

Death Investigation Form for individual 

cases of COVID–19. This EDC Form will 

be used to conduct surveillance for 

COVID–19 on board cruise ships using 

cumulative reports of confirmed 

COVID–19 and COVID–19-like illness, 

which includes acute respiratory illness 

(ARI), influenza-like illness (ILI), 

pneumonia, and additional COVID–19- 

like illness (aCLI) clinical criteria. Data 

points for this form include number of 

travelers (passengers and crew) 

currently onboard; case counts and 

diagnostic testing data for COVID–19 

and COVID–19-like Illness (CLI); 

screening testing of asymptomatic 

travelers, isolation practices, and the 

percentage of travelers who are fully 

vaccinated. 

Access to the online EDC form has 

been provided to cruise lines by the 

Cruise Lines International Association 

(CLIA) and/or CDC. Cruise lines that do 

not have access should contact CLIA or 

CDC. 

To address industry concerns about 

the burden of daily EDC submission, 

CDC will add an option in the online 

form (i.e., a check box) to streamline 

reporting if no cases were identified or 

no testing was conducted for that day. 

Additionally, to reduce reporting 

burden for cruise ships, CDC will 

continue to submit aggregate data to 

seaport authorities, state, local, and 

territorial health departments that 

oversee seaports, federal partners, and 

international maritime public health 

agencies. 

The data collected in the EDC form 

are used to inform CDC’s COVID–19 

Color-Coding System for Cruise Ships. 

These data will greatly increase the 

transparency of the overall health of the 

crew members and passengers, and 

better allow the CDC to manage 

potential outbreaks and offer 

recommendations to the ship and port 

partners. 

The color-coding system is only 

applicable to cruise ships that meet one 

of the following criteria: 

1. Foreign-flagged cruise ships 

currently operating in U.S. waters; or 

2. Foreign-flagged cruise ships 

currently operating outside of U.S. 

waters but planning to return to 

operation in international, interstate, or 

intrastate waterways subject to the 

jurisdiction of the United States; or 

3. U.S.-flagged cruise ships choosing 

to participate in CDC’s COVID–19 

Program for Cruise Ships. 

Status of ships is contingent upon 

daily submission of the EDC form. 

When a cruise ship notifies CDC of 

suspected or confirmed cases of COVID– 

19 on board, CDC determines whether 

an investigation is needed based on a 

predetermined threshold. If an 

investigation is deemed necessary, CDC 

will solicit extra information from the 

cruise ship operator to determine what 

public health interventions may be 

necessary. This investigation gives CDC 

and the cruise industry the ability to 

work closely together to protect the 

health and safety of those on board and 

in communities. 

COVID–19 Testing Capabilities 

As part of CDC’s COVID–19 Program 

for Cruise Ships Operating in U.S. 

Waters, the purpose of testing is to 

quickly identify cases of COVID–19— 

and test and quarantine their close 

contacts who are not fully vaccinated— 

to prevent ongoing transmission 

between voyages. Cruise ship operators 

participating in the program must have 

onboard testing capabilities to test all 

symptomatic crew and passengers for 

COVID–19 and their close contacts. This 

includes having onboard rapid nucleic 

acid amplification test (NAAT) and 

antigen point-of-care equipment that 

meets the requirements specified by 

CDC in technical instructions (e.g., 

authorized by FDA for use in a CLIAwaived setting); however, CDC will no 

longer need to pre-approve these tests. 

Instead, CDC will verify the cruise ship 

operator’s COVID–19 testing capabilities 

during routine cruise ship inspections. 

For the program’s mass crew (and 

passenger, if applicable) testing 

requirement, cruise ship operators may 

use an onboard viral test (NAAT or 

antigen test) or arrange shoreside testing 

at a Clinical Laboratory Improvement 

Amendments (CLIA)-certified laboratory 

so long as it meets the requirements 

specified by CDC in its technical 

instructions. Additionally, cruise ship 

operators must have onboard viral tests 

for routine crew screening testing. Note, 

CDC will no longer need to pre-approve 

these tests. Cruise ship operators may 

contact CDC to request a list of 

acceptable NAAT and antigen tests. 

Port Agreements 

A cruise ship operator that chooses to 

participate in CDC’s COVID–19 Program 

for Cruise Ships in U.S. Waters must 

document the approval of all U.S. port 

and local health authorities where their 

ships intend to dock or make port 

during one or more passenger voyages. 

The agreement must include a port 

operations component, a medical care 

plan component, and a housing 

component meeting the requirements of 

CDC’s technical instructions. Note, 

cruise ship operators will not need to 

produce signed contracts between 

medical and housing facilities when 

submitting their port agreements. Cruise 

lines/brands may submit these 

agreements for all the ships in their 

fleet. 

In lieu of documenting the approval 

of all local health authorities of 

jurisdiction, the cruise ship operator 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices 12709 

may instead submit to CDC a signed 

statement from a local health authority, 

on the health authority’s official 

letterhead, indicating that the health 

authority has declined to participate in 

deliberations and/or sign the port 

agreement, i.e., a ‘‘Statement of NonParticipation.’’ The cruise ship operator 

can submit to CDC documentation of 

attempted communication with the 

local health authority regarding the port 

agreement if a response is not received 

or if the local health authority declines 

to provide a signed statement. 

Additionally, the cruise ship operator 

may enter into a multi-port agreement 

(as opposed to a single port agreement) 

provided that all relevant port and local 

health authorities (including the state 

health authorities) are signatories to the 

agreement. 

During discussions with cruise ship 

operators, port authorities, and state and 

local health authorities, all parties 

requested CDC assistance with the 

required agreements. In response to 

these requests, CDC has created specific 

guidance for additional reference. 

Inspections 

Cruise ships participating in CDC’s 

program are subject to in-person 

inspections by CDC inspectors. The 

cruise ship operator’s properties and 

records must be made available for 

inspection to allow CDC to ascertain 

compliance with its requirements. Such 

properties and records include but are 

not limited to vessels, facilities, 

vehicles, equipment, communications, 

manifests, list of passengers, laboratory 

test results, and employee and 

passenger health records. CDC has 

issued additional technical guidance 

outlining the specific areas that may be 

inspected and corresponding 

recommendations. 

CDC has provided, and will continue 

to provide as necessary, the technical 

instructions for the COVID–19 Program 

for Cruise Ships. CDC will work closely 

with cruise industry, state, territorial, 

and local health authorities, and seaport 

partners to evaluate the program 

components no later than March 18, 

2022, and update them as needed. The 

evaluation will include a review of all 

public health recommendations and 

guidance issued as part of the program 

based on public health conditions and 

available scientific evidence. 

CDC requests OMB approval for an 

estimated 17,532 annual burden hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form or information collection name Number of 

respondents 

Number 

responses 

per 

respondent 

Avg. burden 

per response 

(hours) 

Cruise ship brand/operator ............................. COVID–19 Program for Cruise Ships Notice 

of Participation/Nonparticipation.

20 1 300/60 

Cruise ship brand/operator ............................. Cruise Ship Vaccination Status Classification 130 1 5/60 

Cruise ship parent company ........................... COVID–19 Response Plan ............................ 3 1 2,400/60 

Cruise ship physician ...................................... Enhanced Data Collection (EDC) During 

COVID–19 Pandemic Form (Daily).

130 365 20/60 

Cruise ship physician ...................................... Cruise COVID–19 Case Investigation Worksheet (if necessary).104 1 30/60 

Cruise ship physician ...................................... Cruise COVID–19 Contact Investigation 

Worksheet (if necessary).

24 1 30/60 

Cruise ship brand/operator ............................. Agreement with Health Care Organization 

with signoff from Local Health Authorities.

30 1 600/60 

Cruise ship brand/operator ............................. Agreement with Port of Entry with signoff 

from Local Health Authority.

30 1 600/60 

Cruise ship brand/operator ............................. Agreement with Housing Facility with signoff 

from Local Health Authority.

30 1 600/60 

Cruise ship operator ....................................... Inspections ..................................................... 130 2 120/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–04668 Filed 3–4–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Solicitation of Nominations for 

Appointment to CDC’s Advisory 

Committee to the Director (ACD) 

Health Equity Workgroup (HEW) 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), within 

the Department of Health and Human 

Services (HHS), is seeking nominations 

for membership on the Advisory 

Committee to the Director (ACD) Health 

Equity Workgroup (HEW). The HEW 

will consist of approximately 15 

members who are experts in fields 

associated with health equity; public 

health science and practice; public 

health policy development, analysis, 

and implementation. 

DATES: Nominations for membership on 

the HEW workgroup must be received 

no later than March 17, 2022. Late 

nominations will not be considered for 

membership. 

ADDRESSES: All nominations (cover 

letters and curriculum vitae) should be 

emailed to ACDirector@cdc.gov with the 

subject line: ‘‘Nomination for CDC ACD 

HEW Workgroup.’’ 

FOR FURTHER INFORMATION CONTACT: 

Kerry Caudwell, MPA, Centers for 

Disease Control and Prevention, Office 

of the Chief of Staff, 1600 Clifton Road 

NE, MS H21–10, Atlanta, Georgia 

30329–4027, Telephone: (404) 639– 

7000; Email Address: ACDirector@

cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Background: The purpose of the ACD, 

CDC is to advise the Secretary, HHS, 

and the Director, CDC, on policy and 

broad strategies that will enable CDC to 

fulfill its mission of protecting health 

through health promotion, prevention, 

and preparedness. The ACD, CDC 

consists of up to 15 non-federal 

members, including the Chair, 

knowledgeable in areas pertinent to the 

CDC mission, such as health policy, 

public health, global health, 

preparedness, preventive medicine, the 

faith-based and community-based 

sector, and allied fields. 


khammond on DSKJM1Z7X2PROD with NOTICES